Volume 172, Issue 3 pp. 778-781
Case Report

Somatic mosaicism for the COL7A1 mutation p.Gly2034Arg in the unaffected mother of a patient with dystrophic epidermolysis bullosa pruriginosa

P.C. van den Akker

Corresponding Author

P.C. van den Akker

Department of Dermatology, University of Groningen, University Medical Center Groningen, The Netherlands

Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands

Correspondence

Peter C. van den Akker.

E-mail: [email protected]

Search for more papers by this author
A.M.G. Pasmooij

A.M.G. Pasmooij

Department of Dermatology, University of Groningen, University Medical Center Groningen, The Netherlands

Search for more papers by this author
R. Meijer

R. Meijer

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands

Search for more papers by this author
H. Scheffer

H. Scheffer

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands

Search for more papers by this author
M.F. Jonkman

M.F. Jonkman

Department of Dermatology, University of Groningen, University Medical Center Groningen, The Netherlands

Search for more papers by this author
First published: 12 August 2014
Citations: 14
Funding sources This study was supported by the Netherlands Organization for Health Research and Development (ZonMw) grant 92003541 (PvdA), and the Dutch Vlinderkind (Butterfly Child) Foundation. These organizations were not involved in the design or conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the manuscript, or the decision to submit the manuscript for publication.
Conflicts of interest None declared.

Summary

Dystrophic epidermolysis bullosa (DEB) is a heritable blistering disorder caused by mutations in the type VII collagen gene, COL7A1. Although revertant mosaicism is well known in DEB, ‘forward’ somatic mosaicism, in which a pathogenic mutation arises on a wild-type (WT) background, extending beyond the germ cells, has not been reported. It is therefore unknown what proportion of sporadic dominant DEB (DDEB) cases result from de novo mutations or somatic mosaic parents. In the clinically unaffected mother of a patient with DDEB pruriginosa due to the p.Gly2034Arg mutation, we identified the p.Gly2034Arg mutation in a proportion of lymphocytes and skin cells (mutational load 10–25%). Our data emphasize that forward mosaicism occurs in DDEB and highlight that mutation analysis should always be performed in the parents of sporadic DDEB patients to confirm the de novo status of the mutation. Ultimately, this will reveal the frequency of true de novo mutations and somatic mosaicism in parents, which has important implications for genetic counselling. Our data indicate that the threshold of mutant type VII procollagen to develop DDEB must be higher than 10–25%, which provides a rationale for therapeutic approaches aimed at increasing the WT : mutant type VII collagen ratio.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.